The DOI matches its Crossref record; 188 of the 195 references it cites were found in a registry or an index.
p53, cancer and the immune response
Open accessAbstract
The importance of cancer-cell-autonomous functions of the tumour suppressor p53 (encoded by TP53) has been established in many studies, but it is now clear that the p53 status of the cancer cell also has a profound impact on the immune response. Loss or mutation of p53 in cancers can affect the recruitment and activity of myeloid and T cells, allowing immune evasion and promoting cancer progression. p53 can also function in immune cells, resulting in various outcomes that can impede or support tumour development. Understanding the role of p53 in tumour and immune cells will help in the development of therapeutic approaches that can harness the differential p53 status of cancers compared with most normal tissue.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These mutations can affect the tumor immune microenvironment (TIME) by altering cytokine expression and regulating the tumor’s sensitivity to immune checkpoint inhibitors.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [610]
In the citing paper
“It is widely accepted that gene mutations, including those affecting undruggable proteins, have a significant impact on the efficacy of cancer immunotherapy.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [610]
In the citing paper
“For examples, cancer cells with functional wild-type genes tend to have a desirable cancer-restrictive TIME, while an imbalance in their expression can create a cancer-supportive TIME.610,611”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [610]
In the citing paper
“In brief, the status of genes can influence tumor cells not only through the impact of wild-type gene loss but also through their effects on the TIME.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [610]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Helicobacter pylori Infection and the Development of Gastric Cancer
Uemura, N., Okamoto, S., Yamamoto, S., Matsumura, N., Yamaguchi, S., Yamakido, M., Taniyama, K., Sasaki, N., & Schlemper, R. J. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa001999 · Cited by 4,492
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163
Self-citationIFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751
Mutations in the p53 gene occur in diverse human tumour types
Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hosteller, R., Cleary, K. R., Signer, S. H., Davidson, N. E., Baylin, S., Devilee, P., et al. (1989) · Nature · doi:10.1038/342705a0 · Cited by 2,730
Flagged first, then by citations
7 of the 195 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 301–337 of 337
Wong, S., Xu, L. X., You, W., He, W., Zheng, X., & Qi, Z. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s533208
The GNL3L ‐ MDM2 Interaction Drives Esophageal Squamous Cell Carcinoma Progression
Yang, A., Song, H., & Cheng, Y. (2025) · Cancer Medicine · doi:10.1002/cam4.71146
Immune Allies to Cancer Metastasis
Kudo‐Saito, C. (2025) · Springer eBooks · doi:10.1007/978-3-032-00759-9_56
Research Progress on Acupuncture in Inhibiting Ferroptosis after Intracerebral Hemorrhage
张, 晓. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.15113100
Zhang, S., Qian, J., Chen, Y., & Jin, L. (2025) · Scientific Reports · doi:10.1038/s41598-025-31890-6
Cheng, X., Liu, Z., Chang, H., Liang, W., Li, P., & Gao, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26659738
Song, M., Cheng, H., Zou, H., Ma, K., Lu, L., Wei, Q., Xu, Z., Tang, Z., Zhang, Y., Wang, Y., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25954962
Song, M., Cheng, H., Zou, H., Ma, K., Lu, L., Wei, Q., Xu, Z., Tang, Z., Zhang, Y., Wang, Y., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25955010
Li, Q., Xiao, M., Shi, Y., Hu, J., Bi, T., Wang, C., Yan, L., & Li, X. (2021) · Figshare · doi:10.6084/m9.figshare.16625156
Wei, Y., Cheng, X., Deng, L., Dong, H., Wei, H., Xie, C., Tuo, Y., Li, G., Yu, D., & Cao, Y. B. (2023) · Figshare · doi:10.6084/m9.figshare.22620569
Wang, H.-L., Ye, Z.-M., He, Z.-Y., Huang, L., & Liu, Z.-H. (2023) · Figshare · doi:10.6084/m9.figshare.22602281
Wei, Y., Cheng, X., Deng, L., Dong, H., Wei, H., Xie, C., Tuo, Y., Li, G., Yu, D., & Cao, Y. B. (2023) · Figshare · doi:10.6084/m9.figshare.22620566
Wei, Y., Cheng, X., Deng, L., Dong, H., Wei, H., Xie, C., Tuo, Y., Li, G., Yu, D., & Cao, Y. B. (2023) · Figshare · doi:10.6084/m9.figshare.22620563
Wang, H.-L., Ye, Z.-M., He, Z.-Y., Huang, L., & Liu, Z.-H. (2023) · Figshare · doi:10.6084/m9.figshare.22602272
Martinkova, L., Zatloukalová, P., Kucerikova, M., Friedlová, N., Tylichová, Z., Zavadil-Kokas, F., Hupp, T. R., Coates, P. J., & Vojtesek, B. (2024) · Figshare · doi:10.6084/m9.figshare.26952316
Harnessing the ROS for Cancer Treatment
Osama, A., Zhang, J., & Fang, J. (2025) · Springer eBooks · doi:10.1007/978-3-032-00771-1_255
Christowitz, C., Olivier, D. W., van der Merwe, N., Kotze, M. J., & Engelbrecht, A. (2026) · Translational Oncology · doi:10.1016/j.tranon.2025.102616
CAR-T cell therapy in TP53-mutated CNS lymphoma: overcoming a high-risk genetic barrier
Li, D., Liu, R., Fu, Z., Yang, F., Ma, L., Cao, M., Guo, Y., Deng, B., Chang, A. H., Zheng, Q., et al. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2025.1731589
Martinoli, G., de Biase, D., Ressel, L., Brunetti, B., Avallone, G., Grillini, A., Franceschini, T., Fiorentino, M., Sarli, G., & Bacci, B. (2026) · Scientific Reports · doi:10.1038/s41598-026-41467-6
Aktar, S., Masoudi, M., Moti, D., Gopalan, V., Islam, F., & Lam, A. K.-Y. (2026) · Cancer Medicine · doi:10.1002/cam4.71683 · Cited by 1
Belizário, J. E., Caldeira, I. D. S., Moreira, B., Occhiucci, J. M., Burkhardt, B. R., & Garay-Malpartida, M. (2026) · Receptors · doi:10.3390/receptors5020011
Ma, X., Tian, K., Li, Y., Qin, L., & Guo, X. (2026) · BioMed Research International · doi:10.1155/bmri/2147185
A metabolic crosstalk between liposarcoma and skeletal muscle sustains tumor growth
Romero, J. P. (2020) · theses.fr (ABES) · doi:10.70675/4cf2e124zfd6ez42dazb9baz3a6f801f1847
He, Q., Zou, X., Zheng, C., Zhang, J., Li, J., Hu, L., Zeng, T., Huang, Z., Zeng, P., Wei, J., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0348899
The p53/Mdm2 Pathway in Hepatocellular Carcinoma: From Molecular Pathogenesis to Targeted Therapies
Kirkness, K., & Mann, D. A. (2026) · Livers · doi:10.3390/livers6030039
Ruan, J., Zhang, Y., Zhou, D., Zhang, Y., Zhao, D., Wei, C., Zhang, W., & Li, J. (2026) · Annals of Hematology · doi:10.1007/s00277-026-07068-z
Chromatin folding and function
Moreira-Ferreira, D. N., Silva, J. L., & de Oliveira, G. A. P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-99507-8.00070-6
Verma, D., & Tiwari, M. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.122039
Kirk, A., Stevenson, A., Gu, Q., & Graham, S. V. (2026) · International Journal of Hyperthermia · doi:10.1080/02656736.2026.2692406
Chan, Q., Liang, W., Flisikowska, T., Ebner, F., & Flisikowski, K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1837646
Sang, Y., Min, R., Huang, T., & Zhang, J. (2026) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2026.100539
Wu, X., Sun, T., & Liu, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1891824
de Oliveira, S. B., Alves, A. L. V., Niitsuma, B. N., Antunes, F., Marinho, G. B., Amanatidis, G. L., da Luz, J. C. D. S., BARBOSA, M. O., Zambotti, P. E. O., Rodrigues, O. A., et al. (2026) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-026-05742-4
Amin, M. N., Mostaq, M. S., Jois, S. D. S., Kang, L., & Liu, Y. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48101021
AlRamadneh, T. N., Renuka Jyothi, S., Nayak, P. P., Saheb, L., Ali, A. M., Arora, V., Chauhan, A. S., Garg, G., & Vahdati, S. N. (2026) · Tissue and Cell · doi:10.1016/j.tice.2026.104047
Wannaphut, C., Chiraphapphaiboon, W., Sachs, Z., Gooptu, M., & Sumransub, N. (2026) · Blood Reviews · doi:10.1016/j.blre.2026.101438
BindingDB (2025) · UC San Diego · doi:10.7270/q2571hks
Metadata
- Authors
- Blagih, J., Buck, M. D., & Vousden, K. H.
- Affiliations
- The Francis Crick Institute (GB)
- Venue
- Journal of Cell Science
- Publisher
- The Company of Biologists
- Published
- 2020-03-01
- Volume
- 133
- Issue
- 5
- ISSN
- 0021-9533 (ISSN-L)
- 1477-9137
- OpenAlex
- W3009145316
- Cited by
- 333
- References
- 195
- Citations by year
- 2026: 27 · 2025: 48 · 2024: 63 · 2023: 63 · 2022: 63 · 2021: 51 · 2020: 18
- FWCI
- 5.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Cell Science (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- HighWire Press Open Archive (submittedVersion)
- The Francis Crick Institute (cc-by)
- Funders
- Cancer Research UK (C596/A26855, FC001557)
- Francis Crick Institute
- Medical Research Council (FC001557)
- Wellcome Trust (FC001557)
- Canadian Institutes of Health Research
- European Molecular Biology Organization (ALTF 1096-2018)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- p53, antitumor immunity, immune evasion, TP53 mutation, myeloid cells, T cells, tumor progression, cancer immunotherapy, cancer cells
- MeSH terms
- Humans, Immunity, Mutation, Neoplasms, Tumor Suppressor Protein p53
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
